The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Replimune
Stock and Other Ownership Interests - Replimune
Consulting or Advisory Role - Replimune
Patents, Royalties, Other Intellectual Property - Zentalis
Travel, Accommodations, Expenses - Replimune
Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep/visceral RP1 injection in the registrational cohort of anti–PD-1–failed melanoma patients of the IGNYTE trial.
 
Gino In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Georgiamune (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Michael Wong
Consulting or Advisory Role - Castle Biosciences; Incyte; Regeneron; Replimune
 
Joseph Sacco
Honoraria - Immunocore
Consulting or Advisory Role - BMS; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Eva Muñoz Couselo
Honoraria - BMS; Immunocore; MSD; Novartis; Pierre Fabre; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Menarini; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Georgia Beasley
Honoraria - National Comprehensive Cancer Network
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Delcath Systems (Inst); Istari Oncology (Inst); Oncosec (Inst); Replimune (Inst); Skyline Diagnostics (Inst)
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Regeneron; SERVIER; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Krystal Biotech (Inst); Macrogenics (Inst); Nested Therapeutics (Inst); Pierre Fabre (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - immatics
 
Trisha Wise-Draper
Stock and Other Ownership Interests - High Enroll
Consulting or Advisory Role - Adaptimmune; Adlai Nortye; Caris Life Sciences; EMD Serono; Genmab; Merck; Need; Replimune
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Caris Life Sciences
 
Mohammed Milhem
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Tawnya Bowles
Research Funding - Amgen (Inst); Genentech (Inst)
Other Relationship - Natera (Inst)
 
Katy Tsai
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); Innovent Biologics (Inst); Merck (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Celeste Lebbe
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Inflax; Merck Serono; MSD; Novartis; Pierre Fabre; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Other Relationship - BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IFX (Inst); Immunocore (Inst); Incyte (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; MSD Oncology; Pierre Fabre
 
Adel Samson
Leadership - Leeds Cancer Research Centre
Consulting or Advisory Role - Chugai Pharma; CUBIC; Roche
Research Funding - Cancer Research UK; Histosonics; Medical Research Council; Yorkshire Cancer Research
Expert Testimony - McCollum Consultants; Moore-Barlow LLP
 
Junhong Zhu
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Marcus Viana
No Relationships to Disclose
 
Jeannie Hou
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Honoraria - Bristol-Myers Squibb; Egle; IO Biotech; MaaT Pharma; Merck; MSD; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Bristol-Myers Squibb; Egle; MaaT Pharma; Merck; MSD; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; Ultimovacs
Travel, Accommodations, Expenses - Pierre Fabre